Did you know?

ChinaBio^® Group is a consulting and advisory firm helping life science companies and investors achieve success in China. ChinaBio works with U.S., European and APAC companies and investors seeking partnerships, acquisitions, novel technologies and funding in China.

Learn more >>

Free Newsletter

Have the latest stories on China's life science industry delivered to your inbox daily or weekly - free!

See preview >>

Free Report

State of China Life Science 2022

Free Content

Week in Review

In My Opinion

Free Articles

Subscriber Content

Cellular Bio Starts Phase I China Trial of CD20 CAR-T

publication date: Jun 19, 2019

Cellular Biomedicine, a New York-Shanghai company, has started a China Phase I trial of its CD20 CAR-T candidate in patients who relapsed after CD19 treatment. The patients have either relapsed diffuse large B-cell lymphoma or small B-cell lymphoma. The Phase I trial will enroll an initial 12 patients to evaluate the treatment's safety and efficacy. In addition, Cellular Bio is close to starting trials for its Alpha Fetoprotein T-cell Receptor candidate in liver cancer and its next-gen Tumor Infiltrating Lymphocytes in non-small cell lung cancer patients. More details....

Stock Symbol: (NSDQ: CBMG)

Share this with colleagues:

This article is available for purchase - please click here for details.

Sorry this page is available to subscribers only.
If you're not a subscriber why not subscribe today?

If you are already a subscriber, please login.

If you believe you should have received this message in error, please contact us.

To gain access to the members only content click here to subscribe.

You will be given immediate access to premium content on the site.

Click here to join.